Protocols

MSAC Application 1750: Testing of tumour tissue to detect IDH1 mutations in patients with cholangiocarcinoma to determine eligibility for ivosidenib on the Pharmaceutical Benefits Scheme. 2023.

MSAC Application 1703: Detection of measurable residual disease in patients with acute lymphoblastic leukaemia. 2022.

MSAC Application 1707: Detection of measurable residual disease in patients with acute lymphoblastic leukaemia. 2022.

MSAC Application 1708: Hepatitis Delta Virus (HDV) RNA PCR testing to determine eligibility for PBS-subsidised bulevirtide (HEPCLUDEX) for treatment of HDV. 2022.

MSAC Application 1737: Newborn Bloodspot screening for sickle cell disease and beta Thalassaemia. 2022.

MSAC Application 1627: Point-of-care testing for sexually transmitted infections in areas of high infection burden. 2021.

MSAC Application 1634: Comprehensive genomic profiling of non-small cell lung cancer tumour tissue specimens using next generation sequencing assays. 2021.

MSAC Application 1643: Two testing options for determining eligibility for access to Pharmaceutical Benefits Scheme (PBS) subsidised aducanumab in patients with early stage Alzheimer's Disease (AD). 2021.

MSAC Application 1646: Whole genome sequencing of antimicrobial-resistant pathogens. 2021.

MSAC Application 1660: Diagnostic testing for mesenchymal-epithelial transition Exon 14 (METex14) skipping alterations in non-small cell lung cancer (NSCLC) to determine Pharmaceutical Benefits Scheme (PBS) eligibility for tepotinib treatment. 2021.

MSAC Application 1669: KRAS G12C variant testing to determine eligibility for PBS-subsidised sotorasib second-line therapy in patients with locally advanced or metastatic non small cell lung cancer. 2021.

MSAC Application 1675: Whole Genome Sequencing for the diagnosis of Mitochondrial disease. 2021.

MSAC Application 1680: Genetic testing for childhood hearing impairment. 2021.

MSAC Application 1598: Inheritable cardiac arrhythmia disorders. 2020.

MSAC Application 1618: Testing of tumour tissue to detect BRCA1 or BRCA2 or ATM gene mutations in men with metastatic castration-resistant prostate cancer to determine eligibility for PBS olaparib. 2020.

MSAC Application 1619: Testing of blood to detect germline BRCA1 or BRCA2 gene mutations in patients with metastatic pancreatic cancer to determine eligibility for PBS olaparib. 2020.

MSAC Application 1554: Testing of tumour tissue or blood to detect somatic or germline BRCA1 or BRCA2 gene mutations, in patients with newly diagnosed, advanced (FIGO stage III-IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer. 2019.

MSAC Application 1565: Ig for acquired hypogammaglobulinaemia secondary to haematological malignancies, or post-haemopoietic stem cell transplantation (HSCT). 2019.

MSAC Application 1566: Ig for Myasthenia Gravis. 2019.

MSAC Application 1567: Digital breast tomosynthesis (DBT or 3D mammography). 2019.

MSAC Application 1582: Antibody testing for neuromyelitis optical spectrum disorder. 2019.

MSAC Application 1584: Bone scintigraphy using 99mTc-labelled phosphate derivatives for the diagnosis of transthyretin amyloid cardiomyopathy, to determine eligibility for tafamidis. 2019.

MSAC Application 1506: Programmed cell death ligand 1 (PD-L1) testing to determine PBS access to durvalumab or durvalumab/tremelimumab as 1st line therapy for patients with unresectable Stage IV urothelial cancer. February 2018.

MSAC Application 1508: Pembrolizumab (MK-3475) in mismatch repair deficient Stage IV solid tumours, other than colorectal cancer. February 2018.

MSAC Application 1511: Extended half-life clotting factor concentrates for the treatment of haemophilia A and B. February 2018.

MSAC Application 1518: Endoscopic visual laser ablation of the prostate (VLAP) for benign prostatic hyperplasia. May 2018.

MSAC Application 1519: Tisagenlecleucel (CTL019) for treatment of refractory/relapsed CD19-positive leukaemia and lymphoma. May 2018.

MSAC Application 1534: Heritable mutations associated with familial hypercholesterolaemia. September 2018.

MSAC Application 1496: Micro-invasive glaucoma surgery (MIGS) device implantation (external to Schlemm's canal) in patients with mild-to-moderate primary open-angle glaucoma. April 2017.

MSAC Application 1483: Trabecular bypass micro-invasive glaucoma surgery (MIGS) device implantation in patients with mild-to-moderate primary open-angle glaucoma. April 2017.

MSAC Application 1468: SIR-Spheres^(R) Y-90 resin microspheres for the treatment of hepatic metastases which are secondary to colorectal cancer and are not suitable for resection or ablation, used in combination with systemic chemotherapy. April 2017.

MSAC Application 1490: Breast magnetic resonance imaging (MRI) for breast implant-associated anaplastic large cell lymphoma. September 2017.

MSAC Application 1452: Pembrolizumab (MK-3475) in mismatch repair deficient stage IV colorectal carcinoma, December 2016.

MSAC Application 1453: PD-L1 (Programmed Death-1 Ligand) immunohistochemistry testing for access to pembrolizumab for patients with unresectable metastatic mesothelioma, December 2016.

MSAC Application 1457: PD-L1 (Programmed Death 1 Ligand) IHC (immunohistochemistry) testing for access to pembrolizumab as first-line therapy for patients with unresectable or metastatic bladder cancer ineligible for cisplatin-based therapy, December 2016.

MSAC Application 1366: Transient Elastography at 50Hz for diagnosis of Liver Fibrosis in patients with confirmed Hepatitis B or confirmed Hepatitis C, May 2015.

MSAC Application 1400: Protocol to guide the assessment of Clinical Neuropsychology Assessment (CNA), August 2015.

MSAC Application 1408: Protocol to guide the assessment of a prognostic RT-qPCR test for ER+ve, HER2-ve primary breast cancer, August 2015.

MSAC Application 1165: Protocol to guide the assessment of Preimplantation Genetic Diagnosis, May 2014.

MSAC Application 1216: Protocol to guide the assessment of testing for hereditary mutations in the Cystic Fibrosis conductance Transmembrane Regulator (CFTR) gene, October 2014.

MSAC Application 1267: Final decision analytic protocol (DAP) to guide the assessment of HbA1c testing for the diagnosis of diabetes mellitus, January 2013.

MSAC Application 1293: Final decision analytic protocol (DAP) to guide the assessment of Epidermal Growth Factor Receptor (EGFR) gene mutation testing for eligibility for afatinib treatment in patients with stage IIIB or stage IV non-small cell lung cancer (NSCLC), January 2013.

MSAC Application 1269: Final decision analytic protocol (DAP) to guide the assessment of computed tomography colonography for the diagnosis or exclusion of colorectal neoplasia, January 2013.

MSAC Application 1310: Final decision analytic protocol (DAP) to guide the assessment of optical coherence tomography for assessment of central retinal thickness in the presence of macular oedema secondary to central retinal vein occlusion, January 2013.

MSAC Application 1206: Final decision analytic protocol (DAP) to guide the assessment of single balloon enteroscopy for obscure gastrointestinal bleeding, January 2013.

MSAC Application 1196: Final decision analytic protocol (DAP) to guide the assessment repetitive Transcranial Magnetic Stimulation as a treatment for major depression, January 2013.

MSAC Application 1243: Consultation decision analytic protocol (DAP) to guide the assessment of removal of imbedded corneal foreign body, June 2013.

MSAC Application 1181: Consultation decision analytic protocol (DAP) to guide the assessment of Retinal Photography with a Non-Mydriatic Retinal Camera (RP-NMRC) in people with diagnosed diabetes, October 2013.

MSAC Application 1332: Consultation decision analytic protocol (DAP) to guide the assessment of external expert opinions for morphological pathology (history and cytopathology), October 2013.

Parsons, J, Merlin, T, Street, J. Review Protocol of selected Medicare-funded skin services, 2013.

MSAC Application 1267: Final decision analytic protocol (DAP) to guide the assessment of HbA1c testing for the diagnosis of diabetes mellitus, January 2013.

MSAC Application 1293: Final decision analytic protocol (DAP) to guide the assessment of Epidermal Growth Factor Receptor (EGFR) gene mutation testing for eligibility for afatinib treatment in patients with stage IIIB or stage IV non-small cell lung cancer (NSCLC), January 2013.

MSAC Application 1269: Final decision analytic protocol (DAP) to guide the assessment of computed tomography colonography for the diagnosis or exclusion of colorectal neoplasia, January 2013.

MSAC Application 1310: Final decision analytic protocol (DAP) to guide the assessment of optical coherence tomography for assessment of central retinal thickness in the presence of macular oedema secondary to central retinal vein occlusion, January 2013.

MSAC Application 1206: Final decision analytic protocol (DAP) to guide the assessment of single balloon enteroscopy for obscure gastrointestinal bleeding, January 2013.

MSAC Application 1196: Final decision analytic protocol (DAP) to guide the assessment repetitive Transcranial Magnetic Stimulation as a treatment for major depression, January 2013.

MSAC Application 1243: Consultation decision analytic protocol (DAP) to guide the assessment of removal of imbedded corneal foreign body, June 2013.

MSAC Application 1181: Consultation decision analytic protocol (DAP) to guide the assessment of Retinal Photography with a Non-Mydriatic Retinal Camera (RP-NMRC) in people with diagnosed diabetes, October 2013.

MSAC Application 1332: Consultation decision analytic protocol (DAP) to guide the assessment of external expert opinions for morphological pathology (history and cytopathology), October 2013.

Parsons, J, Merlin, T, Street, J. Review Protocol of selected Medicare-funded skin services, 2013.

MSAC Application 1151: Protocol to guide the assessment of molecular testing for the diagnosis or prediction of Long QT Syndrome, May 2011. 

MSAC Application 1153: Protocol to guide the assessment of genetic testing for hereditary mutation of the von Hippel-Lindau (VHL) Gene, September 2011.  

MSAC Application 1163: Final protocol to guide the assessment of HER2 testing in advanced gastric cancer, October 2011.